Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?

被引：23

作者：

Kumarasamy, N. ^{[1
,3
]}

Patel, Atul ^{[2
,3
]}

Pujari, Sanjay ^{[3
,4
]}

机构：

[1] YRG CARE Med Ctr, Voluntary Hlth Serv, Madras 600113, Tamil Nadu, India

[2] Vedant Inst Med Sci, Ahmadabad, Gujarat, India

[3] Inst Infect Dis, Pune, Maharashtra, India

[4] HIVMAI, Pune, Maharashtra, India

来源：

INDIAN JOURNAL OF MEDICAL RESEARCH | 2011年 / 134卷 / 06期

基金：

英国惠康基金;

关键词：

Antiretroviral drugs; antiretroviral therapy; ART; CD4; HIV; IRIS; viral load; RECONSTITUTION INFLAMMATORY SYNDROME; HIV-INFECTED PATIENTS; CD4 CELL COUNTS; COST-EFFECTIVENESS ANALYSIS; ZIDOVUDINE-INDUCED ANEMIA; LONG-TERM EFFICACY; LINE VIRAL LOAD; IMMUNE RECONSTITUTION; RISK-FACTORS; DRUG-RESISTANCE;

D O I：

10.4103/0971-5916.92626

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

With the rapid scale up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment guideline for the management of HIV disease continue to change. This review focuses on evolving science on Indian policy - antiretroviral therapy initiation, which drugs to start with, when to change the initial regimen and what to change.

引用

页码：787 / 800

页数：14

共 50 条

[21] Commentary: When to start and what to use in children - recommendations and rationale
Siberry, George
Tindyebwa, Denis
AIDS, 2014, 28 : S133 - S135
[22] CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose
Calcagno, Andrea
Barco, Ambra
Trunfio, Mattia
Bonora, Stefano
CURRENT HIV/AIDS REPORTS, 2018, 15 (01) : 84 - 91
[23] Clinical considerations when switching antiretroviral therapy
Fernandez, Analuz
Imaz, Arkaitz
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (07) : 565 - 577
[24] Antiretroviral Therapy for the Prevention of HIV Transmission: What Will It Take?
McNairy, Margaret L.
El-Sadr, Wafaa M.
CLINICAL INFECTIOUS DISEASES, 2014, 58 (07) : 1003 - 1011
[25] When and how to start antiretroviral treatment in HIV-infected adults?
Hoen, B.
JOURNAL DES ANTI-INFECTIEUX, 2011, 13 (02) : 117 - 121
[26] What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis
Burke, Rachael M.
Rickman, Hannah M.
Singh, Vindi
Corbett, Elizabeth L.
Ayles, Helen
Jahn, Andreas
Hosseinipour, Mina C.
Wilkinson, Robert J.
MacPherson, Peter
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 (07)
[27] When to switch for antiretroviral treatment failure in resource-limited settings?
Vekemans, Marc
John, Laurence
Colebunders, Robert
AIDS, 2007, 21 (09) : 1205 - 1206
[28] The unanswered question: when to initiate antiretroviral therapy in children with HIV infection
Abrams, Elaine J.
CURRENT OPINION IN HIV AND AIDS, 2007, 2 (05) : 416 - 425
[29] A decade of antiretroviral therapy in Uganda: what are the emerging causes of death?
Kiragga, Agnes N.
Mubiru, Frank
Kambugu, Andrew D.
Kamya, Moses R.
Castelnuovo, Barbara
BMC INFECTIOUS DISEASES, 2019, 19 (1)
[30] What is the effect of pill burden on adherence to HIV antiretroviral therapy?
Sutton, S. Scott
Ahuja, Divya
Magagnoli, Joseph
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2016, 29 (11): : 16 - 17

← 1 2 3 4 5 →